ImmunityBio: Making Strides, But Beware The Hype (Rating Downgrade) [Seeking Alpha]
ImmunityBio, Inc. (IBRX)
Company Research
Source: Seeking Alpha
ImmunityBio's Anktiva is approved for NMIBC and expanding globally, with key clinical catalysts in 2026 and promising signals in NSCLC and cell therapy. Despite 700% net product revenue growth to $113 million, ImmunityBio's high debt load and unprofitability remain significant risks. I shift ImmunityBio stock to a Hold rating, expecting a more favorable entry point as market enthusiasm likely cools before long-term goals materialize. Klaus Vedfelt/DigitalVision via Getty Images Topline Summary and Update Market and analyst sentiment on ImmunityBio, Inc. ( IBRX ) has waxed and waned since I have been watching the company starting back in late 2023 , prior to the approval This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensati
Show less
Read more
Impact Snapshot
Event Time:
IBRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IBRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IBRX alerts
High impacting ImmunityBio, Inc. news events
Weekly update
A roundup of the hottest topics
IBRX
News
- Why ImmunityBio Stock Is Skyrocketing Again Today [Yahoo! Finance]Yahoo! Finance
- ImmunityBio (IBRX) Extends Gains to 10th Day on 700% Anktiva Sales Jump; Time to Book Profits? [Yahoo! Finance]Yahoo! Finance
- Ford & BYD reportedly in talks to partner, PNC rises on earnings [Yahoo! Finance Canada]Yahoo! Finance Canada
- ImmunityBio Says Potential Lymphoma Therapy Extends Complete Response to 15 Months [Yahoo! Finance]Yahoo! Finance
- ImmunityBio Advances First-Line BCG Naive NMIBC Program with Enrollment Exceeding Expectations and Positive Interim Analysis for ANKTIVA® Plus BCG [Yahoo! Finance]Yahoo! Finance
IBRX
Earnings
- 5/12/25 - Miss
IBRX
Sec Filings
- 1/16/26 - Form 144
- 1/15/26 - Form 8-K
- 1/14/26 - Form 8-K
- IBRX's page on the SEC website